To analyze BrdU incorporation, cells were labeled with 10 M BrdU after which cells were collected, washed and, fixed in 70% EtOH. are sustained by the numerous oligosaccharide/oligonucleotide binding (OB)-folds present on each of the three subunits (2;3). OB-folds in DNA binding domains A and B (DBD-A and DBD-B) in the central region of the p70 subunit contribute most of the binding energy for RPA-ssDNA interactions (2). Individual OB-folds are compact modular domains populated with hydrophobic and basic amino acids. These structural features make the OB-folds an attractive target for development of small molecule inhibitors (SMIs) of DNA binding activity. Inhibiting RPA-DNA interactions has the potential to impact numerous DNA metabolic pathways that are differentially active in cancer cells. In DNA replication, RPA inhibition can be used D-glutamine to exploit the highly proliferative nature of cancer cells which is characterized by a large population of cells in S-phase. Consistent with this, a recent clinical trial correlated disease stage and metastasis in colon cancer with increased RPA p70 and p34 expression (4). RPA is also essential for several DNA repair pathways in the cell including nucleotide excision repair (NER). Cisplatin, a common chemotherapeutic used in the treatment of various cancers, induces its cytotoxic effect by forming intrastrand covalent DNA adducts that are repaired primarily by the NER pathway (5). Consistent with the role of NER in the repair of cisplatin-induced DNA damage, resistance to this treatment has been observed to be influenced by DNA repair capacity (6;7). Consequently, cisplatin treatment, in conjunction with decreased RPA ssDNA binding activity, would be expected to result in decreased efficiency of cellular repair of cisplatin-DNA adducts and increased cytotoxicity. Thus, targeting RPA has the potential not only for single agent activity but also to sensitize cancer cells to therapies that induce DNA damage and genetic instability, such as cisplatin, etoposide and ionizing radiation (IR). We present the identification and development of the first small molecule that inhibits the ssDNA binding activity of RPA. Cellular RPA inhibition results in the inability to enter S phase, D-glutamine cytotoxicity and synergistic activity with the chemotherapeutic agents cisplatin and etoposide. This is the first characterization of a small molecule that is able to inhibit the ssDNA binding activity of RPA and presents a novel chemotherapeutic target both as a single agent and in conjunction with commonly used chemotherapeutics. Materials and Methods protein analysis Small molecule inhibitors were obtained from ChemDiv and resuspended in DMSO. Compound 505 was independently synthesized and structure confirmed by mass spectrometry analysis. Human RPA was purified as previously described (8). Fluorescence Anisotropy based DNA binding assays were performed with 40 nM RPA and 20 nM 5fluoroscein-labeled ss-dT12 DNA as previously described (9). EMSAs were performed in 20 L reactions containing 25 nM RPA, 25 nM 5[32P]-labeled 34-base pair DNA as previously described (8). Molecular Modeling Molecular modeling of compound 505 with the central DNA binding domain of RPA p70 (1FGU) was performed using Autodock 4.2 (10). Three independent grids established 60? in each dimension to encompass either the interdomain region, DBD-A or DBD-B. Semi-flexible automated ligand docking was performed using the Monte Carlo based simulated annealing and locality search algorithms. The most stable complexes were selected based on binding energies from multiple analyses. Coordinates of the final docked complexes were displayed with PyMOL. Flow Cytometry H460 cells were analyzed for apoptosis using an Annexin V-FITC/Propidium iodide (PI) Vybrant Apoptosis Assay Kit (Invitrogen), according to manufacturers instructions. Cells were plated Rabbit Polyclonal to Cofilin at a density of 1 1 104 cells/cm2 for 24 hours and then treated with compound 505 for 48 hours. Following plating and treatment of H460 cells, adherent and non-adherent cells were collected, D-glutamine processed, and analyzed on a BD FACScan flow cytometer. Data was analyzed using WinMDI software (The Scripps Research Institute, San Diego, CA). Cell cycle analysis was performed by PI staining. Briefly, cells were plated and treated with compound, collected and then washed.
To analyze BrdU incorporation, cells were labeled with 10 M BrdU after which cells were collected, washed and, fixed in 70% EtOH
Categories
- 34
- 5- Receptors
- A2A Receptors
- ACE
- Acetylcholinesterase
- Adenosine Deaminase
- Adenylyl Cyclase
- Adrenergic ??2 Receptors
- Alpha2 Adrenergic Receptors
- Annexin
- Antibiotics
- ATPase
- AXOR12 Receptor
- Ca2+ Ionophore
- Cannabinoid
- Cannabinoid (GPR55) Receptors
- CB2 Receptors
- CCK Receptors
- Cell Metabolism
- Cell Signaling
- Cholecystokinin2 Receptors
- CK1
- Corticotropin-Releasing Factor1 Receptors
- DHCR
- DMTases
- DNA Ligases
- DNA Methyltransferases
- Dopamine D1 Receptors
- Dopamine D3 Receptors
- Dopamine D4 Receptors
- Endothelin Receptors
- EP1-4 Receptors
- Epigenetics
- Exocytosis & Endocytosis
- Fatty Acid Synthase
- Flt Receptors
- GABAB Receptors
- GIP Receptor
- Glutamate (Kainate) Receptors
- Glutamate (Metabotropic) Group III Receptors
- Glutamate (NMDA) Receptors
- Glutamate Carboxypeptidase II
- Glycogen Phosphorylase
- Glycosyltransferase
- GnRH Receptors
- Heat Shock Protein 90
- hERG Channels
- Hormone-sensitive Lipase
- IKK
- Imidazoline Receptors
- IMPase
- Inositol Phosphatases
- Kisspeptin Receptor
- LTA4 Hydrolase
- M1 Receptors
- Matrixins
- Melastatin Receptors
- mGlu Group III Receptors
- mGlu5 Receptors
- Monoamine Oxidase
- Motilin Receptor
- My Blog
- Neutrophil Elastase
- Nicotinic (??4??2) Receptors
- NKCC Cotransporter
- NMU Receptors
- Nociceptin Receptors
- Non-Selective
- Non-selective 5-HT
- OP3 Receptors
- Opioid, ??-
- Orexin2 Receptors
- Other
- Other Oxygenases/Oxidases
- Other Transcription Factors
- p38 MAPK
- p53
- p56lck
- PAF Receptors
- PDPK1
- PKC
- PLA
- PPAR
- PPAR??
- Proteasome
- PTH Receptors
- Ras
- RNA Polymerase
- Serotonin (5-HT2B) Receptors
- Serotonin Transporters
- Sigma2 Receptors
- Sodium Channels
- Steroid Hormone Receptors
- Tachykinin NK1 Receptors
- Tachykinin NK2 Receptors
- Tachykinin, Non-Selective
- Telomerase
- Thyrotropin-Releasing Hormone Receptors
- Topoisomerase
- trpp
- Uncategorized
- USP
Recent Posts
- 2012) using the Phenotypic Characteristic Search for human strains with markers for resistance to Adamantane, Oseltamivir, or both drugs
- Tissue were homogenized into single-cell suspensions and put through red bloodstream cell lysis
- A phase I/II study investigated the safety and efficacy of concurrent local palliative RT and durvalumab (PD-L1 inhibitor) in 10 patients with unresectable or metastatic advanced solid tumors [136]
- We believe that this hypothesis-generating study could open new avenues for exploring oxidative stress as a potential pathogenetic and, hypothetically, therapeutic target for mitigating CLL strong class=”kwd-title” Keywords: Leukemia, Lymphocytic, Gilbert’s, Syndrome Gilbert’s syndrome (GS) is the most common inherited disorder of bilirubin glucuronidation
- Such costs aren’t simple for tertiary-care hospitals in growing countries sometimes, since these already are powered by minimal budget which switches into provision of fundamental medical services mostly, laboratory, radiology, pharmacy services, and bed space
Tags
a 67 kDa type I transmembrane glycoprotein present on myeloid progenitors
and differentiation. The protein kinase family is one of the largest families of proteins in eukaryotes
Apoptosis
bladder
brain
breast
cell cycle progression
cervix
CSP-B
Cyproterone acetate
EGFR) is the prototype member of the type 1 receptor tyrosine kinases. EGFR overexpression in tumors indicates poor prognosis and is observed in tumors of the head and neck
EM9
endometrium
erythrocytes
F3
Goat polyclonal to IgG H+L)
Goat polyclonal to IgG H+L)Biotin)
GRK4
GSK1904529A
Igf1
Mapkap1
monocytes andgranulocytes. CD33 is absent on lymphocytes
Mouse monoclonal to CD33.CT65 reacts with CD33 andtigen
Palomid 529
platelets
PTK) or serine/threonine
Rabbit Polyclonal to ARNT.
Rabbit polyclonal to BMPR2
Rabbit Polyclonal to CCBP2.
Rabbit Polyclonal to EDG4
Rabbit polyclonal to EIF4E.
Rabbit polyclonal to IL11RA
Rabbit polyclonal to LRRIQ3
Rabbit Polyclonal to MCM3 phospho-Thr722)
Rabbit Polyclonal to RBM34
SB 216763
SKI-606
SNX-5422
STK) kinase catalytic domains. Epidermal Growth factor receptor
stomach
stomach and in squamous cell carcinoma.
TNFSF8
TSHR
VEGFA
vulva